Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Total Non-Current Liabilities: 2014-2025

Historic Total Non-Current Liabilities for Viking Therapeutics (VKTX) over the last 8 years, with Sep 2025 value amounting to $318,000.

  • Viking Therapeutics' Total Non-Current Liabilities fell 57.88% to $318,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $318,000, marking a year-over-year decrease of 57.88%. This contributed to the annual value of $630,000 for FY2024, which is 32.69% down from last year.
  • According to the latest figures from Q3 2025, Viking Therapeutics' Total Non-Current Liabilities is $318,000, which was down 22.44% from $410,000 recorded in Q2 2025.
  • In the past 5 years, Viking Therapeutics' Total Non-Current Liabilities registered a high of $1.5 million during Q1 2022, and its lowest value of $318,000 during Q3 2025.
  • Moreover, its 3-year median value for Total Non-Current Liabilities was $766,000 (2024), whereas its average is $769,818.
  • Data for Viking Therapeutics' Total Non-Current Liabilities shows a maximum YoY tumbled of 57.88% (in 2025) over the last 5 years.
  • Viking Therapeutics' Total Non-Current Liabilities (Quarterly) stood at $1.3 million in 2022, then decreased by 25.71% to $936,000 in 2023, then tumbled by 32.69% to $630,000 in 2024, then crashed by 57.88% to $318,000 in 2025.
  • Its last three reported values are $318,000 in Q3 2025, $410,000 for Q2 2025, and $502,000 during Q1 2025.